Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6% and the iShares Biotechnology ETF (IBB) advancing by 1.3%.
Nuvation Bio (NUVB) stock was up more than 3% after the company said the FDA has approved its supplemental New Drug Application for IBTROZI (taletrectinib), a ROS1 inhibitor for locally advanced or metastatic ROS1-positive non-small cell lung cancer.